Government of Pakistan
Ministry of National Health Services, Regulations and Coordination
(Drug Regulatory Authority of Pakistan)
**********

Islamabad, the 22nd July, 2016.

NOTIFICATION

S.R.O. 638 (I)/2016. - In exercise of the powers conferred by clause (a) of section 7 of the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of 2012) read with section 12 of the Drugs Act, 1976 (XXXI of 1976), the Drug Regulatory Authority of Pakistan (DRAP) with the approval of the Federal Government is pleased to fix maximum retail prices subject to the conditions specified in paragraphs 2 and 3 of this notification, as under:-

1. 1.43% for scheduled drugs, 2.002% for non-scheduled drugs and 2.86% for lower priced drugs over and above the maximum retail prices as fixed by the Federal Government.

2. This notification shall not be applicable on all sub-judice cases related to pricing issues including notification No11-2/2013-DDC(P) dated 29th November, 2013 till final adjudication of such cases.

3. The maximum retail prices (MRPs) shall be subject to the following conditions, namely:-

   (a) the price increase shall not be applicable on the batches manufactured before affecting the increase of authorized rates by the Federal Government. No recall of drugs of already marketed batches shall be allowed;

   (b) the revised MRPs shall be printed on the label in the manner prescribed by the Drugs (Labeling and Packing) Rules, 1986;

   (c) no manufacturer, importer, retailer, hospital, clinic, wholeseller or distributor shall be allowed to affix stickers, overlapping or masking of prices. However in order to save

the packing materials, manufacturers can reprint maximum retail price on the same through laser inkjet after masking the previous MRPs for packing of new stocks;

(d) calculations of revised MRPs, duly signed and stamped by the Managing Director or Managing Partner or CEO or any authorized person on their behalf, shall be intimated to the Authority (Division of Costing and Pricing) at least 15 days prior to affecting the increase;

(e) revised price list shall be submitted in hard copy and uploaded on the DRAP website or as prescribed by the Authority from time to time; and

(f) evidence for authenticity of the existing approved prices shall be submitted with declaration that the calculation have been made in accordance with the provisions of the Drug Pricing Policy-2015 and the approved increased rate by the Federal Government.

---

[No.F.11-13/2016-DDC (P)]

(Amanullah)
Director Costing & Pricing

The Manager,
Printing Corporation of Pakistan Press,
Islamabad